CTLA4 and neoplasm: Synergizing their corresponding blockades would abrogate Treg cell-mediated immunosuppressive effects and enhance CD8+ and NK cell function within tumor tissues, demonstrating improved safety profiles over CTLA-4 and PD-1 inhibitors.